Abstract
Behcet's syndrome (BD) is a controversial, chronic, and episodic condition that is autoimmune in origin and causes systemic vasculitis in the arteries and genital veins. BD is consistently associated with depression, with an incidence of 86% upon the first appearance of symptoms and disorders of the disease. However, few studies have looked at depression and other psychiatric disorders, such as anxiety, in the context of comorbidity with BD. The aim of this review is to identify articles that focus on the relation between BD and depression as a comorbidity. The studies found revealed a consistently high incidence of depression in the BD population, even when compared with other chronic pathologies including Rheumatoid Arthritis and Psoriasis, although there was a limitation in the use of scales and other tools for assessment and control of comorbid symptoms, moreover there are no studies linking the drugs used in the BD treatment of each patient and the symptoms present in each case. This review clearly shows the lack of research in which depression scores are analyzed in relation to the medications used by individual patients. Additionally, the use of additional scales is necessary to increase the knowledge about the nature and consequences of depression as comorbidity of BD.
Keywords: Behcet's disease, Behcet's syndrome, chronic disease, depression.
CNS & Neurological Disorders - Drug Targets
Title:Depression as a Comorbidity in Behcet's Syndrome
Volume: 13 Issue: 6
Author(s): Natalia P. de Oliveira Ribeiro, Alexandre R. de Mello Schier, Tamires M. Pessoa, Valeska M. Pereira, Sergio Machado, Oscar Arias-Carrion, Antonio E. Nardi and Adriana Cardoso
Affiliation:
Keywords: Behcet's disease, Behcet's syndrome, chronic disease, depression.
Abstract: Behcet's syndrome (BD) is a controversial, chronic, and episodic condition that is autoimmune in origin and causes systemic vasculitis in the arteries and genital veins. BD is consistently associated with depression, with an incidence of 86% upon the first appearance of symptoms and disorders of the disease. However, few studies have looked at depression and other psychiatric disorders, such as anxiety, in the context of comorbidity with BD. The aim of this review is to identify articles that focus on the relation between BD and depression as a comorbidity. The studies found revealed a consistently high incidence of depression in the BD population, even when compared with other chronic pathologies including Rheumatoid Arthritis and Psoriasis, although there was a limitation in the use of scales and other tools for assessment and control of comorbid symptoms, moreover there are no studies linking the drugs used in the BD treatment of each patient and the symptoms present in each case. This review clearly shows the lack of research in which depression scores are analyzed in relation to the medications used by individual patients. Additionally, the use of additional scales is necessary to increase the knowledge about the nature and consequences of depression as comorbidity of BD.
Export Options
About this article
Cite this article as:
Ribeiro P. de Oliveira Natalia, Schier R. de Mello Alexandre, Pessoa M. Tamires, Pereira M. Valeska, Machado Sergio, Arias-Carrion Oscar, Nardi E. Antonio and Cardoso Adriana, Depression as a Comorbidity in Behcet's Syndrome, CNS & Neurological Disorders - Drug Targets 2014; 13 (6) . https://dx.doi.org/10.2174/1871527313666140612114115
DOI https://dx.doi.org/10.2174/1871527313666140612114115 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Oxidative Stress Modulation Through Habitual Physical Activity
Current Pharmaceutical Design Fibrates and Microvascular Complications in Diabetes - Insight from the FIELD Study
Current Pharmaceutical Design Anti-CD20 Antibody in Primary Sjogren's Syndrome Managemen
Current Pharmaceutical Biotechnology Gene Polymorphisms and Pharmacogenetics in Rheumatoid Arthritis
Current Genomics Emerging Treatment Strategies and Potential Therapeutic Targets in Primary Sjogrens Syndrome
Inflammation & Allergy - Drug Targets (Discontinued) Toxicities of Immunosuppressive Treatment of Autoimmune Neurologic Diseases
Current Neuropharmacology Does Caffeine Affect Cardiovascular Responses?
Vascular Disease Prevention (Discontinued) Repositioning Drugs for Rare Immune Diseases: Hopes and Challenges for a Precision Medicine
Current Medicinal Chemistry The Role of Estrogen and Estrogen-Related Drugs in Cardiovascular Diseases
Current Drug Metabolism Medication-Induced Acute Abdominal Pain: Evaluation with CT Imaging
Current Medical Imaging Pulmonary Hypertension: Clinical Presentation, Diagnosis, Treatment,and Dana Point World Symposium Highlights
Current Respiratory Medicine Reviews Nerve Growth Factor in Neurological and Non-Neurological Diseases: Basic Findings and Emerging Pharmacological Prospectives
Current Pharmaceutical Design The Rationale and Development of New Drugs to Treat HIV Infection
Medicinal Chemistry Triggering Receptor Expressed on Myeloid Cells (TREM) Family and the Application of Its Antagonists
Recent Patents on Anti-Infective Drug Discovery Anesthetic Cardioprotection: The Role of Adenosine
Current Pharmaceutical Design Cardiac Involvement in ANCA (+) and ANCA (-) Churg-Strauss Syndrome Evaluated by Cardiovascular Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued) Central Nervous System Manifestations in Systemic Lupus Erythematosus
Current Rheumatology Reviews Omalizumab for Asthma: Indications, Off-Label Uses and Future Directions
Recent Patents on Inflammation & Allergy Drug Discovery Innate and Adaptive Immune Responses in Chronic HCV Infection
Current Drug Targets Evaluation of Serum Calprotectin Level and Disease Activity in Patients with Rheumatoid Arthritis
Current Rheumatology Reviews